Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Last trade$4.52
Day change+$0.095 (+2.15%)
Day range$4.35 – $4.61
Volume209,942
Market cap$290M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$289.77M
Price / earnings
—
Price / book
4.7×
Price / sales
1.43×
EV / sales
1.66×
EV / EBITDA
-8.13×
Profitability
Earnings per share
-$0.85
Return on assets
-31.15%
Return on equity
-90.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.91×
Current ratio
2.58×
Quick ratio
1.66×
Cash ratio
0.17×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TMCI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$48.25M
$45.38M
$47.2M
$62.52M
$50.21M
$47.39M
$52.57M
$68.71M
Cost of revenue
$9.9M
$9.77M
$9.79M
$12.12M
$10.51M
$9.64M
$10.68M
$13.23M
Gross profit
$38.35M
$35.61M
$37.41M
$50.4M
$39.71M
$37.75M
$41.89M
$55.48M
Selling, general and administrative
$45.39M
$46.19M
$49.95M
$51.78M
$50.7M
$49.23M
$51.91M
$50.47M
Research and development
$4.49M
$4.38M
$4.62M
$4.54M
$4.68M
$5.5M
$5.56M
$5.21M
Total operating expenses
$49.72M
$50.36M
$54.57M
$56.32M
$55.29M
$54.6M
$57.48M
$55.68M
Operating income
-$11.37M
-$14.76M
-$17.17M
-$5.92M
-$15.58M
-$16.85M
-$15.58M
-$204K
Interest expense
-$1.58M
-$1.56M
-$1.57M
-$1.35M
-$1.34M
-$1.32M
-$1.31M
-$1.31M
Income before taxes
-$12.62M
-$15.87M
-$17.96M
-$9.39M
-$16.26M
-$17.4M
-$15.92M
-$501K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$12.62M
-$15.87M
-$17.96M
-$9.39M
-$16.26M
-$17.4M
-$15.92M
-$501K
Net income attributable to common shareholders
-$12.62M
-$15.87M
-$17.96M
-$9.39M
-$16.26M
-$17.4M
-$15.92M
-$501K
EBITDA
-$9.34M
-$12.87M
-$16.27M
-$3.11M
-$12.81M
-$14.28M
-$13.12M
$2.03M
Basic earnings per share
-$0.19
-$0.24
-$0.28
-$0.15
-$0.26
-$0.28
-$0.25
-$0.01
Diluted earnings per share
-$0.19
-$0.24
-$0.28
-$0.15
-$0.26
-$0.28
-$0.25
-$0.01
Recent news
Company coverage with links to the original publishers.
Treace Medical Concepts reported a Q3 loss of $0.19 per share, beating consensus estimates of $0.26 loss by 26.92%. Revenue of $48.25 million slightly exceeded estimates by 1.18%, though it declined from $50.21 million year-over-year. The stock has gained 70.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Tandem Diabetes Care reported a Q3 loss of $0.1 per share, beating consensus estimates of -$0.27 loss, representing a 62.96% earnings surprise. Revenue reached $283.69 million, surpassing estimates by 6.94% and up from $249.25 million year-ago. However, the stock has underperformed the market by 13.3% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.
UFP Technologies reported quarterly earnings of $2.88 per share, beating consensus estimates of $2.63 and surpassing revenue expectations. The company has outperformed the S&P 500 by 17.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Treace Medical Concepts, a peer in the Medical-Instruments industry, is expected to report a quarterly loss.
Alphatec (ATEC) reported quarterly earnings of $0.09 per share, missing the consensus estimate of $0.11, with revenues also falling short of expectations. The stock has declined 45.6% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Instruments industry ranks in the bottom 40% of Zacks industries, suggesting broader sector weakness.
Law firm Johnson Fistel is investigating potential securities fraud and breaches of fiduciary duties for four publicly traded companies, alleging false statements, misleading disclosures, and operational misrepresentations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.